Literature DB >> 2005449

Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease.

R A Nordyke1, F I Gilbert.   

Abstract

Since hypothyroidism is commonplace after treatment of Graves' disease with radioiodine, the goal should be cure of hyperthyroidism rather than avoidance of hypothyroidism. To find the optimal dose to accomplish cure, we treated 605 patients with stepwise increasing doses of 3, 4, 5, 6, 8, and 10 mCi, analyzing the relationship of dose, age, sex, gland weight, and thyroidal uptake to cure. Estimates of cure at doses above 10 mCi were made from the literature. Cure was directly related to dose between 5 and 10 mCi. There was no significant relationship between cure and age (chi-square, p = 0.74), sex (chi-square, p = 0.12), and 24-hr uptake if over 30% (chi-square for slope, p greater than 0.10). Cure and gland weight had an inverse relationship (chi-square for slope, 0.01 less than p less than 0.02). We concluded that the optimal 131I dose for curing hyperthyroidism is approximated by starting with 10 mCi and increasing it for unusually large glands or for special patient circumstances.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005449

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  Scarred atrophic thyroid after I-131 therapy for Graves' disease documented at autopsy.

Authors:  Wei-Jen Shih; Bonnie Mitchell; Jennifer C Schott
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

2.  A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid.

Authors:  M Schiavo; M C Bagnara; I Calamia; I Bossert; E Ceresola; F Massaro; M Giusti; A Pilot; G Pesce; M Caputo; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

3.  Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves' disease.

Authors:  X Li; G Wang; Z Lu; M Chen; J Tan; X Fang
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

4.  An informatics-based chronic disease practice: case study of a 35-year computer-based longitudinal record system.

Authors:  R A Nordyke; C A Kulikowski
Journal:  J Am Med Inform Assoc       Date:  1998 Jan-Feb       Impact factor: 4.497

5.  Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison.

Authors:  Martin A Walter; Mirjam Christ-Crain; Christian Schindler; Jan Müller-Brand; Beat Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-11       Impact factor: 9.236

6.  Late and transient increases in free T4 after radioiodine treatment for Graves' disease.

Authors:  A D Stensvold; R Jorde; J Sundsfjord
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

7.  Effect of adjuvant lithium on thyroxine (T4) concentration after radioactive iodine therapy.

Authors:  Emmanuel NiiBoye Hammond; Mboyo-Di-Tamba Heben Willy Vangu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

8.  Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose.

Authors:  F Massaro; L Vera; M Schiavo; C Lagasio; M Caputo; M Bagnasco; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

9.  Radioiodine I-131 for the therapy of graves' disease.

Authors:  Malik Mumtaz; Lim Shueh Lin; Khaw Chong Hui; Amir Sharifuddin Mohd Khir
Journal:  Malays J Med Sci       Date:  2009-01

10.  The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level.

Authors:  H I Adamali; J Gibney; D O'Shea; M Casey; T J McKenna
Journal:  Ir J Med Sci       Date:  2007-07-14       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.